Previous 10 | Next 10 |
Vir Biotechnology (NASDAQ: VIR) and Axonics (NASDAQ: AXNX) are two of the fastest-growing healthcare companies in terms of revenue. Vir raised $142.9 million when it went public with an initial public offering (IPO) in 2019, while Axonics raised $120 million with its IPO in 2018...
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will participate in the Piper Sandler Healthcare Conference on December 1, 2022. Axonics is scheduled to presen...
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced it ranked No. 4 on the Deloitte Technology Fast 500 , a ranking of the 500 fastest growing tech...
Axonics, Inc. (AXNX) Q3 2022 Earnings Conference Call October 31, 2022 16:30 ET Company Participants Neil Bhalodkar - Vice President of Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President & Chief Financial Officer Conferenc...
Axonics Modulation Technologies press release ( NASDAQ: AXNX ): Q3 GAAP EPS of -$0.34 beats by $0.14 . Revenue of $70.4M (+50.1% Y/Y) beats by $7.42M . Sacral neuromodulation revenue was $56.9 million, of which $55.6 million was generated in the U.S. ...
Generated record quarterly revenue of $70 million, an increase of 50% year over year Fiscal year 2022 revenue guidance raised to $262 million, an increase of 45% year over year Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developi...
Axonics ( NASDAQ: AXNX ) is trading 5.6% lower after Needham downgraded rating to hold from buy. The analyst Mike Matson sees a less favorable risk/reward profile after Needham's urologist survey suggested the company may have difficulty driving upside to consensus 202...
Summary 100% technical buy signals. 7 new highs and up 5.40% in the last month. Analysts price targets from 70 to 95. The Chart of the Day belongs to the medical devices company Axonics ( AXNX ). I found the stock by sorting Barchart's All-Time High list firs...
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the first patient implants in Canada with the Axonics F15™, the company’s newly devel...
Summary Axonics looks well-positioned to continue its recent upside on the chart, with a number of idiosyncratic tailwinds yet to be recognized. The recent equity underwriting of $35mm is noted, although this is hardly a risk given intended use for capital initiatives. Shares ...
News, Short Squeeze, Breakout and More Instantly...
Axonics Modulation Technologies Inc. Company Name:
AXNX Stock Symbol:
NASDAQ Market:
Axonics Modulation Technologies Inc. Website:
Axonics, Inc. (NASDAQ: AXNX) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 0.09% on the day to $68.5. Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulat...
Generated record revenue, gross margin and net income in 2Q24 Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results f...
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...